BriaCell Therapeutics Corp.
BCTXW · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $7 | $5 | $6 |
| G&A Expenses | $2 | $1 | $2 | $1 |
| SG&A Expenses | $2 | $1 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $8 | $9 | $6 | $7 |
| Operating Income | -$8 | -$8 | -$6 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$8 | -$8 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS | -4.31 | -4.26 | -1,640.18 | -0.35 |
| % Growth | -1.2% | 99.7% | -468,522.9% | – |
| EPS Diluted | -4.31 | -4.26 | -1,640.18 | -0.35 |
| Weighted Avg Shares Out | 2 | 2 | 0 | 18 |
| Weighted Avg Shares Out Dil | 2 | 2 | 0 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | $19 | -$6 | -$7 |
| % Margin | – | – | – | – |